Precision Medicine News and Research

RSS

Kinexus introduces new KiNET-Antibody Microarray website

Kinexus Bioinformatics Corporation, a world-leader in molecular intelligence research, announced a major expansion in its KiNET DataBank for the study of cell communication systems with the launch of the KiNET-Antibody Microarray website.

13 Jul 2011

IGR, IPSEN sign 3 year medical oncology agreement

IPSEN, a global biopharmaceutical company represented by Claude Bertrand, Executive Vice President, R&D and Chief Scientific Officer, and Institut de cancérologie Gustave Roussy, a leading international cancer center represented by Professor Alexander Eggermont, General Director, today announced the signature of a partnership in the area of medical oncology to leverage the combined expertises of their respective R&D teams.

12 Jul 2011

Mammograms should be personalized based on woman's age, breast density

Mammograms should not be done on a one-size fits all basis, but instead should be personalized based on a woman's age, the density of her breasts, her family history of breast cancer and a number of other factors including her own values.

5 Jul 2011

DiagnoCure, Signal Genetics enter commercialization collaboration for Previstage GCC Colorectal Cancer Staging Test

Signal Genetics, a privately held predictive genetic testing company focusing on oncology, and DiagnoCure, Inc., a life sciences company that develops and commercializes high-value cancer diagnostic tests, today announced a collaboration arrangement valued at US$13.3M over the first five years.

29 Jun 2011

A*STAR-CSI scientists discover how body uses single communication system to decide fate of stem cells

Scientists from the Genome Institute of Singapore (GIS), an institute of the Agency for Science, Technology and Research (A*STAR), in collaboration with the Cancer Science Institute of Singapore (CSI), have discovered how the body uses a single communication system to decide the fate of stem cells.

24 Jun 2011

New VAAST software tool can identify disease-causing mutations in rare genetic disorders

Harnessing the new generation of rapid, highly accurate gene-sequencing techniques, a research team has identified the disease-causing mutation in a newly characterized rare genetic disease, by analyzing DNA from just a few individuals.

24 Jun 2011

Supreme Court accepts case that could shape field of personalized medicine

The U.S. Supreme Court, accepting a case that will shape the burgeoning business of personalized medicine, agreed to consider what types of diagnostic medical tests can be patented. The justices agreed today to hear an appeal from the Mayo Clinic, which is challenging a lower court decision backing two patents for determining the dosage of medicines to treat stomach diseases.

22 Jun 2011

Novel method of disguising nanoparticles as red blood cells to fight cancer

Researchers at the University of California, San Diego have developed a novel method of disguising nanoparticles as red blood cells, which will enable them to evade the body's immune system and deliver cancer-fighting drugs straight to a tumor. Their research was published this week in the online Early Edition of the Proceedings of the National Academy of Sciences.

22 Jun 2011

Study investigates effects of dopamine replacement therapy on cognition in patients with Parkinson's

Dopamine replacement therapy, which is used to manage motor symptoms associated with Parkinson's disease, can, at times, adversely affect cognition.

15 Jun 2011

Research reveals how humans of different ancestry process polyunsaturated fat

Over the past decade, much progress has been made regarding the understanding and promise of personalized medicine. Scientists are just beginning to consider the impact of gene-diet interactions in different populations in regards to disease prevention and treatment.

15 Jun 2011

New findings from Deplin clinical trial on major depressive disorder presented at NCDEU

New findings from a multi-center, randomized, placebo-controlled clinical study of Deplin 15mg added to commonly prescribed antidepressants known as selective serotonin reuptake inhibitors showed that all patients who achieved remission at 30 days using Deplin 15mg adjuvant therapy, and who chose to enter a 12 month maintenance phase, maintained their remission after a year of treatment.

14 Jun 2011

Life Technologies, Fox Chase partner to provide next-generation sequencing analysis of solid tumors

Fox Chase Cancer Center, one of the nation's leading cancer research and treatment institutions, today announced it has entered into an agreement with Life Technologies Corporation that will underpin a new program to provide next-generation sequencing analysis of solid tumors.

14 Jun 2011

MDxHealth extends agreement with Merck for use of MGMT assay in brain cancer trials

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, announced today that it will extend its agreement with Merck KGaA, Darmstadt, Germany, for use of MDxHealth's MGMT assay in Merck KGaA's brain cancer clinical trials.

9 Jun 2011

Rio Tinto Alcan donates $10M to CHUM and MUHC Joint Corporate Campaign

The Fondation du Centre hospitalier de l'Université de Montréal (CHUM) and the McGill University Health Centre Foundation (MUHC) officially announce a significant gift of 10 million dollars donated by Rio Tinto Alcan to their Joint Corporate Campaign.

9 Jun 2011

European hematologists raise alarm on insufficient research money for blood disorders

European hematologists raise the alarm on the insufficient research money for blood disorders. "Blood cancers kill over 95,000 in the EU every year; the EU must be made aware that more research funds are needed", states Professor Robin Foa, President of the European Hematology Association (EHA) at their annual congress in London.

8 Jun 2011

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced efficacy and safety data from the BRIM3 trial, a large, randomized, multi-center Phase 3 clinical study of vemurafenib in patients with previously untreated metastatic melanoma with the BRAFV600 mutation.

6 Jun 2011

Customizing targeted therapies to each tumor's molecular characteristics may effectively treat cancer

Customizing targeted therapies to each tumor's molecular characteristics, instead of a one-size-fits-all approach by tumor type, may be more effective for some types of cancer, according to research conducted by The University of Texas MD Anderson Cancer Center.

4 Jun 2011

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

In data presented at The American Society of Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has a favorable safety profile and extends survival by two to three times more than the current median survival rate.

4 Jun 2011

Nuvera announces results of blinded study on breast cancer assay for taxane chemotherapy response

Nuvera Biosciences, a molecular diagnostics company that develops gene-based diagnostic assays for personalized medicine in cancer, announced the results of a blinded validation study on its breast cancer assay for taxane chemotherapy response.

4 Jun 2011

Rheonix to receive U.S. patent for powerful microfluidic platform

Rheonix, Inc., developer of the Rheonix CARD system that provides a powerful microfluidic platform for the evolving molecular diagnostics industry, announced that on June 14, 2011 the U.S. Patent and Trademark Office will issue Patent Number 7,959,875, "Microfluidic Chips and Assay Systems," and on April 13, 2011 it allowed Patent Application Number 11/594,444, "Microfluidic Systems," to the Company.

3 Jun 2011

Precision Medicine News and Research

Kinexus introduces new KiNET-Antibody Microarray website

IGR, IPSEN sign 3 year medical oncology agreement

Mammograms should be personalized based on woman's age, breast density

DiagnoCure, Signal Genetics enter commercialization collaboration for Previstage GCC Colorectal Cancer Staging Test

A*STAR-CSI scientists discover how body uses single communication system to decide fate of stem cells

New VAAST software tool can identify disease-causing mutations in rare genetic disorders

Supreme Court accepts case that could shape field of personalized medicine

Novel method of disguising nanoparticles as red blood cells to fight cancer

Study investigates effects of dopamine replacement therapy on cognition in patients with Parkinson's

Research reveals how humans of different ancestry process polyunsaturated fat

New findings from Deplin clinical trial on major depressive disorder presented at NCDEU

Life Technologies, Fox Chase partner to provide next-generation sequencing analysis of solid tumors

MDxHealth extends agreement with Merck for use of MGMT assay in brain cancer trials

Rio Tinto Alcan donates $10M to CHUM and MUHC Joint Corporate Campaign

European hematologists raise alarm on insufficient research money for blood disorders

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

Customizing targeted therapies to each tumor's molecular characteristics may effectively treat cancer

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

Nuvera announces results of blinded study on breast cancer assay for taxane chemotherapy response

Rheonix to receive U.S. patent for powerful microfluidic platform

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News